|
1
|
Yang L, Xie HJ, Li YY, Wang X, Liu XX and
Mai J: Molecular mechanisms of platinum-based chemotherapy
resistance in ovarian cancer (Review). Oncol Rep. 47:822022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Penny SM: Ovarian cancer: An overview.
Radiol Technol. 91:561–575. 2020.PubMed/NCBI
|
|
3
|
Wallis B, Bowman KR, Lu P and Lim CS: The
challenges and prospects of p53-Based therapies in ovarian cancer.
Biomolecules. 13:1592023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Terp SK, Stoico MP, Dybkær K and Pedersen
IS: Early diagnosis of ovarian cancer based on methylation profiles
in peripheral blood cell-free DNA: A systematic review. Clin
Epigenetics. 15:242023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chandrasekaran A and Elias KM: Synthetic
lethality in ovarian cancer. Mol Cancer Ther. 20:2117–2128. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang XW, Wu YS, Xu TM and Cui MH: CAR-T
cells in the treatment of ovarian cancer: A promising cell therapy.
Biomolecules. 13:4652023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moufarrij S, Dandapani M, Arthofer E,
Gomez S, Srivastava A, Lopez-Acevedo M, Villagra A and Chiappinelli
KB: Epigenetic therapy for ovarian cancer: Promise and progress.
Clin Epigenetics. 11:72019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang C, Gao S and Hou J: ERCC1 expression
and platinum chemosensitivity in patients with ovarian cancer: A
meta-analysis. Int J Biol Markers. 35:12–19. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang M, Jia K, Wang L, Li W, Chen B, Liu
Y, Wang H, Zhao S, He Y and Zhou C: Alterations of DNA damage
response pathway: Biomarker and therapeutic strategy for cancer
immunotherapy. Acta Pharm Sin B. 11:2983–2994. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hamilton G and Rath B: Pharmacogenetics of
platinum-based chemotherapy in non-small cell lung cancer:
Predictive validity of polymorphisms of ERCC1. Expert Opin Drug
Metab Toxicol. 14:17–24. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zazuli Z, Vijverberg S, Slob E, Liu G,
Carleton B, Veltman J, Baas P, Masereeuw R and Maitland-van der Zee
AH: Genetic variations and cisplatin nephrotoxicity: A systematic
review. Front Pharmacol. 9:11112018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Muallem MZ, Braicu I, Nassir M, Richter R,
Sehouli J and Arsenic R: ERCC1 expression as a predictor of
resistance to platinum-based chemotherapy in primary ovarian
cancer. Anticancer Res. 34:393–399. 2014.PubMed/NCBI
|
|
13
|
Tang N, Lyu D, Zhang Y and Liu H:
Association between the ERCC1 polymorphism and platinum-based
chemotherapy effectiveness in ovarian cancer: A meta-analysis. BMC
Womens Health. 17:432017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rosell R, Taron M, Camps C and
López-Vivanco G: Influence of genetic markers on survival in
non-small cell lung cancer. Drugs Today (Barc). 39:775–786. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lenz HJ: Pharmacogenomics and colorectal
cancer. Adv Exp Med Biol. 587:211–231. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li W, Jie Z, Li Z, Liu YI, Gan Q, Mao Y
and Wang X: ERCC1 siRNA ameliorates drug resistance to cisplatin in
gastric carcinoma cell lines. Mol Med Rep. 9:2423–2428. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wilson JM and Engelhardt J: Adenovirus
vectors for gene therapy. Biotechnol Adv. 15:7691997. View Article : Google Scholar
|
|
18
|
Berkey SE, Thorne SH and Bartlett DL:
Oncolytic virotherapy and the tumor microenvironment. Adv Exp Med
Biol. 1036:157–172. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lundstrom K: Viral vectors in gene
therapy: Where do we stand in 2023? Viruses. 15:6982023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stella GM, Marchiò C, Bari E, Ferrarotti
I, Bertuccio FR, Di Gennaro A, Abbott DM, Putignano P, Campo I,
Torre ML and Corsico AG: The genes-stemness-secretome interplay in
malignant pleural mesothelioma: Molecular dynamics and clinical
hints. Int J Mol Sci. 24:34962023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Strapcova S, Takacova M, Csaderova L,
Martinelli P, Lukacikova L, Gal V, Kopacek J and Svastova E:
Clinical and pre-clinical evidence of carbonic anhydrase IX in
pancreatic cancer and its high expression in pre-cancerous lesions.
Cancers (Basel). 12:20052020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bao MH and Wong CC: Hypoxia, metabolic
reprogramming and drug resistance in liver cancer. Cells.
10:17152021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kopecka J, Salaroglio IC, Perez-Ruiz E,
Sarmento-Ribeiro AB, Saponara S, De Las Rivas J and Riganti C:
Hypoxia as a driver of resistance to immunotherapy. Drug Resist
Updat. 59:1007872021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)). method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Loren P, Saavedra N, Saavedra K, De Godoy
Torso N, Visacri MB, Moriel P and Salazar LA: Contribution of
MicroRNAs in chemoresistance to cisplatin in the top five deadliest
cancer: An updated review. Front Pharmacol. 13:8310992022.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao T, Bai J, Zou Q, Chen F and Xie Y:
Insulin in combination with cisplatin induces the apoptosis of
ovarian cancer cells via p53 and JNK activation. Mol Med Rep.
16:9095–9101. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lheureux S, Gourley C, Vergote I and Oza
AM: Epithelial ovarian cancer. Lancet. 393:1240–1253. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lheureux S, Braunstein M and Oza AM:
Epithelial ovarian cancer: Evolution of management in the era of
precision medicine. CA Cancer J Clin. 69:280–304. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Long J, Yang Y, Kang T, Zhao W, Cheng H,
Wu Y, Du T, Liu B, Li Y, Luo F and Gou M: Ovarian cancer therapy by
VSVMP gene mediated by a paclitaxel-enhanced nanoparticle. ACS Appl
Mater Interfaces. 9:39152–39164. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhong Q, Wen YJ, Yang HS, Luo H, Fu AF,
Yang F, Chen LJ, Chen X, Qi XR, Lin HG, et al: Efficient inhibition
of cisplatin-resistant human ovarian cancer growth and prolonged
survival by gene transferred vesicular stomatitis virus matrix
protein in nude mice. Ann Oncol. 19:1584–1591. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Unno Y, Shino Y, Kondo F, Igarashi N, Wang
G, Shimura R, Yamaguchi T, Asano T, Saisho H, Sekiya S and
Shirasawa H: Oncolytic viral therapy for cervical and ovarian
cancer cells by Sindbis virus AR339 strain. Clin Cancer Res.
11:4553–4560. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Galanis E, Hartmann LC, Cliby WA, Long HJ,
Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ Jr, Aderca I,
Zollman PJ, et al: Phase I trial of intraperitoneal administration
of an oncolytic measles virus strain engineered to express
carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res.
70:875–882. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chebouti I, Kuhlmann JD, Buderath P, Weber
S, Wimberger P, Bokeloh Y, Hauch S, Kimmig R and Kasimir-Bauer S:
ERCC1-expressing circulating tumor cells as a potential diagnostic
tool for monitoring response to platinum-based chemotherapy and for
predicting post-therapeutic outcome of ovarian cancer. Oncotarget.
8:24303–24313. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bösmüller H, Haitchi-Petnehazy S,
Webersinke G, Marschon R, Roithmeier F, Stummvoll W, Fehm T,
Klier-Richter M, Bonzheim I, Staebler A and Fend F: Intratumoral
lymphocyte density in serous ovarian carcinoma is superior to ERCC1
expression for predicting response to platinum-based therapy.
Virchows Arch. 459:183–191. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Innao V, Rizzo V, Allegra AG, Musolino C
and Allegra A: oncolytic viruses and hematological malignancies: A
new class of immunotherapy drugs. Curr Oncol. 28:159–183. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chintala NK, Choe JK, McGee E, Bellis R,
Saini JK, Banerjee S, Moreira AL, Zauderer MG, Adusumilli PS and
Rusch VW: Correlative analysis from a phase I clinical trial of
intrapleural administration of oncolytic vaccinia virus (Olvi-vec)
in patients with malignant pleural mesothelioma. Front Immunol.
14:11129602023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vijver SV, Danklmaier S, Pipperger L,
Gronauer R, Floriani G, Hackl H, Das K and Wollmann G: Prediction
and validation of murine MHC class I epitopes of the recombinant
virus VSV-GP. Front Immunol. 13:11007302023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cohn DE, Sill MW, Walker JL, O'Malley D,
Nagel CI, Rutledge TL, Bradley W, Richardson DL, Moxley KM and
Aghajanian C: Randomized phase IIB evaluation of weekly paclitaxel
versus weekly paclitaxel with oncolytic reovirus (Reolysin) in
recurrent ovarian, tubal, or peritoneal cancer: An NRG
Oncology/Gynecologic Oncology Group study. Gynecol Oncol.
146:477–483. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Moreno V, Barretina-Ginesta MP,
García-Donas J, Jayson GC, Roxburgh P, Vázquez RM, Michael A,
Antón-Torres A, Brown R, Krige D, et al: Safety and efficacy of the
tumor-selective adenovirus enadenotucirev with or without
paclitaxel in platinum-resistant ovarian cancer: A phase 1 clinical
trial. J Immunother Cancer. 9:e0036452021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liao H, Zhang L, Lu S, Li W and Dong W:
KIFC3 promotes proliferation, migration, and invasion in colorectal
cancer via PI3K/AKT/mTOR signaling pathway. Front Genet.
13:8489262022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hinz N and Jücker M: Distinct functions of
AKT isoforms in breast cancer: A comprehensive review. Cell Commun
Signal. 17:1542019. View Article : Google Scholar : PubMed/NCBI
|
